Episode

EULAR 2026 Daily Podcast Day 4c

Podcast
Rheumnow Podcast
Published
Jun 8, 2026
Duration seconds
1494
Processing state
not_requested
Canonical source
https://rheumnow.podbean.com/e/eular-2026-daily-podcast-day-4c/
Audio
https://mcdn.podbean.com/mf/web/q5qbtu5fc72kfxzc/EULAR_2026_Daily_Podcast_Day_4c96xir.mp3
JSON
/v1/public/podcasts/rheumnow-podcast-587987/episodes/eular-2026-daily-podcast-day-4c
Markdown
/podcast/rheumnow-podcast-587987/eular-2026-daily-podcast-day-4c.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/rheumnow-podcast-587987/episodes/eular-2026-daily-podcast-day-4c/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/rheumnow-podcast-587987/eular-2026-daily-podcast-day-4c.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Guselkumab Delivers Across the PsA Disease Spectrum: APEX TrialRA BRIDGE and RA BRANCH trials: Baricitinib and VTE RiskImproving Referrals for Inflammatory Arthritis"Combination Therapy: Off the Shelf Allogenic NK and Rituximab in Rheumatic Disease